Saladax Biomedical, a company that develops, manufactures, and markets drugs for psychiatry and oncology, recently signed a distribution agreement with Thermo Fisher Scientific, a biotechnology research company, to expand global access to high-quality therapeutic drug monitoring assays that support clinicians in optimizing patient outcomes.
“We are excited to enter this strategic partnership with Thermo Fisher to expand physician and patient access to Saladax’s clinically important therapeutic drug monitoring solutions,” said Sal Salamone, CEO and founder of Saladax Biomedical, which is headquartered in Bethlehem, Pa. “This partnership is a major step in making these important tests available to healthcare professionals on a global scale.”
Therapeutic drug monitoring methods are often slow. Saladax’s rapid method provides accurate measurements of drug concentrations and allows clinicians to better tailor therapies, reduces toxicity, and improves patient outcomes. Its assays are designed to run on existing instrumentation.
Under the agreement, Thermo Fisher will distribute Saladax’s therapeutic drug monitoring (TDM) tests through its global commercial organization, giving more laboratories the means to provide clinicians with timely and actionable drug level information.
“Saladax’s proprietary TDM assays complement Thermo Fisher’s existing TDM portfolio and most importantly, expand the availability of comprehensive solutions that help improve patient outcomes,” said Patrick Jones, president of the clinical diagnostics business within Thermo Fisher.